# Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct06921785/  
OnCo record `nct06921785` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tremelimumab, Rilvegostomig, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, now recruiting.

## Summary

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT06921785 by AstraZeneca, with 1220 participants planned, started 2025-05-06 and due to reach its primary completion in 2030-03-15. Interventions recorded: Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06921785
- Phase: 3
- Setting: A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Sponsor: AstraZeneca
- Enrolled: 1220

## Sources

- ClinicalTrials.gov NCT06921785: https://clinicaltrials.gov/study/NCT06921785

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06921785.json